Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
Public ClinicalTrials.gov record NCT04317040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment
Study identification
- NCT ID
- NCT04317040
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 234 participants
Conditions and interventions
Conditions
Interventions
- Efprezimod alfa Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2020
- Primary completion
- Oct 19, 2020
- Completion
- Oct 19, 2020
- Last update posted
- Feb 7, 2023
2020
United States locations
- U.S. sites
- 10
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Baptist Health Research Institute | Jacksonville | Florida | 32207 | — |
| Anne Anundel Medical Center | Annapolis | Maryland | 21401 | — |
| Institute of Human Virology, University of Maryland Baltimore | Baltimore | Maryland | 21201 | — |
| Shady Grove Medical Center | Rockville | Maryland | 20850 | — |
| White Oak Medical Center | Silver Spring | Maryland | 20904 | — |
| Cooper University Hospital | Camden | New Jersey | 08103 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| The Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| University of Texas at Houston | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04317040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04317040 live on ClinicalTrials.gov.